Comparative diagnostic performance of saliva PCR and dried blood spot PCR for congenital cytomegalovirus detection: a systematic review and meta-analysis Authors: Benedict Osei Tawiah, Enoch Aninagyei, Ibrahim Anyass Goumboundi, Nana Gyeni Ntim, Richard K. D. Ephraim, Theophilus Adiku Published: 2026 ABSTRACT BackgroundCongenital cytomegalovirus (cCMV) infection is a leading cause of non-genetic sensorineural hearing loss and neurodevelopmental impairment. This study aimed to systematically evaluate and compare the diagnostic accuracy of saliva polymerase chain reaction (PCR) and dried blood spot (DBS) PCR for detecting cCMV in newborns.MethodsA systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, Cochrane Library, ProQuest, and Google Scholar were searched for studies published between 2010 and 2025. Eligible studies reported sufficient data to construct 2 × 2 contingency tables and used urine PCR or culture as reference standards. Pooled sensitivity, specificity, likelihood ratios, diagnostic odds ratios, and summary receiver operating characteristic (SROC) curves were estimated using random-effects and bivariate models.ResultsNineteen studies comprising 103,669 neonates were included. Saliva PCR demonstrated high pooled sensitivity (0.95, 95% CI: 0.91–0.97) and perfect specificity (1.00, 95% CI: 0.99–1.00). In contrast, DBS PCR showed lower pooled sensitivity (0.72, 95% CI: 0.45–0.89) while maintaining high specificity (0.99, 95% CI: 0.92–1.00). Subgroup analysis revealed significantly higher sensitivity for saliva PCR compared with DBS PCR (p = 0.004). SROC analysis indicated superior overall diagnostic performance for saliva PCR (AUC = 0.72) relative to DBS PCR (AUC = 0.56). Substantial heterogeneity was observed, particularly among DBS studies.ConclusionSaliva PCR demonstrates superior sensitivity and overall diagnostic accuracy for early detection of cCMV compared with DBS PCR, while both methods show high specificity. These findings support saliva PCR as the preferred modality for newborn screening where feasible, while DBS PCR may serve as a complementary or alternative approach in large-scale or resource-limited settings.Clinical trialNot applicable. Introduction Congenital cytomegalovirus (cCMV) infection is recognized as the most common congenital viral infection globally and a leading non-genetic cause of permanent sensorineural hearing loss and neurodevelopmental disability in children [1]. The birth prevalence of cCMV has been estimated at approximately 0.67% of live births worldwide, and even infants who are asymptomatic at birth may later develop significant sequelae such as delayed-onset hearing loss or developmental impairments [2]. Early and accurate diagnosis of cCMV in the newborn period is crucial because antiviral treatment and early intervention services have been shown to improve outcomes, particularly in infants with central nervous system involvement [3]. The gold standard for diagnosing cCMV infection traditionally involves PCR testing of urine collected within the first three weeks of life, a method noted for high sensitivity and specificity but limited in practicality for large-scale implementation due to logistical challenges in specimen collection [4]. Saliva PCR has emerged as a promising alternative, offering non-invasive, rapid, and more feasible sampling, with studies reporting high diagnostic accuracy and near-perfect sensitivity and specificity compared to urine PCR [5]. DBS PCR testing, another modality that leverages samples routinely collected for newborn metabolic screening, has shown variable sensitivity across studies but remains of interest for retrospective diagnosis and potential screening use given its high specificity and ease of integration into existing workflows [6]. Despite the increasing use of saliva and DBS PCR for cCMV detection in research and clinical settings, reported diagnostic performance metrics have been heterogeneous, and comparative evaluation of these methods in a systematic framework is lacking. Given the expanding body of evidence, an updated and comprehensive synthesis of diagnostic accuracy data is needed to better inform clinical practice and public health policy regarding newborn cCMV screening. This systematic review and meta-analysis aim to quantitatively evaluate the sensitivity, specificity, and overall diagnostic performance of saliva PCR and DBS PCR in detecting congenital CMV infection in newborns. Methods Protocol and registration This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [7]. The protocol has been registered in the International Prospective Register of Systematic Reviews (PROSPERO), with the registration number PROSPERO 2026 CRD420261306188. Eligibility criteria Studies were eligible for inclusion if they assessed the diagnostic accuracy of saliva PCR or dried blood spot (DBS) PCR for the detection of congenital cytomegalovirus (cCMV) infection in newborns. The eligibility criteria were structured using a PICO framework: Population: Newborns/neonates screened for cCMV infection.Index tests: Saliva PCR and DBS PCR.Comparator (reference standard): Urine PCR and/or viral culture.Outcomes: Diagnostic accuracy measures including sensitivity, specificity, and data required to construct 2 × 2 contingency tables. Population: Newborns/neonates screened for cCMV infection. Population: Newborns/neonates screened for cCMV infection. Index tests: Saliva PCR and DBS PCR. Index tests: Saliva PCR and DBS PCR. Comparator (reference standard): Urine PCR and/or viral culture. Comparator (reference standard): Urine PCR and/or viral culture. Outcomes: Diagnostic accuracy measures including sensitivity, specificity, and data required to construct 2 × 2 contingency tables. Outcomes: Diagnostic accuracy measures including sensitivity, specificity, and data required to construct 2 × 2 contingency tables. Included studies reported sufficient data to construct 2 × 2 contingency tables (true positives, false positives, false negatives, and true negatives). Both prospective and retrospective observational studies were considered. Studies were excluded if they lacked extractable diagnostic accuracy data, did not clearly describe the reference standard, or employed non-standardized or insufficiently described PCR protocols. In addition, studies utilizing single-target (single-plex) PCR assays were excluded to reduce methodological heterogeneity and ensure comparability across studies. Reviews, case reports, editorials, conference abstracts without full data, animal studies, and non-human studies were also excluded. Information sources and search strategy A comprehensive literature search was conducted in PubMed, the Cochrane Library, ProQuest and Google Scholar from 2010 to 2025. Search strategies combined Medical Subject Headings and free-text terms related to the congenital cytomegalovirus, saliva PCR, and DBS PCR (Table 1). In addition, the reference lists of all included studies were manually screened to identify potentially relevant articles not captured by the database searches. Table 1Electronic database search strategies for studies on congenital cytomegalovirus diagnostic accuracyDatabaseSearch StrategyPubMed(“Cytomegalovirus Infections, Congenital“[MeSH] OR “congenital cytomegalovirus“[Title/Abstract] OR “congenital CMV“[Title/Abstract]) AND (diagnosis[Title/Abstract] OR diagnostic[Title/Abstract] OR “diagnostic accuracy“[Title/Abstract] OR sensitivity[Title/Abstract] OR specificity[Title/Abstract]) AND (PCR[Title/Abstract] OR “polymerase chain reaction“[Title/Abstract] OR saliva[Title/Abstract] OR urine[Title/Abstract] OR blood[Title/Abstract] OR “dried blood spot“[Title/Abstract])Cochrane Library(cytomegalovirus OR CMV) AND (congenital OR perinatal OR newborn OR neonate OR neonatal) AND (diagnos* OR sensitivity OR specificity OR “predictive value*” OR ROC OR “receiver operating characteristic”)ProQuestallintitle: “diagnostic accuracy” OR sensitivity OR specificity OR PCR OR saliva OR urine OR DBS OR blood OR newborn OR neonate “congenital cytomegalovirus”Google Scholar(“congenital cytomegalovirus” OR “congenital CMV”) AND (“diagnostic accuracy” OR sensitivity OR specificity) AND (“dried blood spot” OR DBS OR saliva OR urine) AND PCR Table 1Electronic database search strategies for studies on congenital cytomegalovirus diagnostic accuracyDatabaseSearch StrategyPubMed(“Cytomegalovirus Infections, Congenital“[MeSH] OR “congenital cytomegalovirus“[Title/Abstract] OR “congenital CMV“[Title/Abstract]) AND (diagnosis[Title/Abstract] OR diagnostic[Title/Abstract] OR “diagnostic accuracy“[Title/Abstract] OR sensitivity[Title/Abstract] OR specificity[Title/Abstract]) AND (PCR[Title/Abstract] OR “polymerase chain reaction“[Title/Abstract] OR saliva[Title/Abstract] OR urine[Title/Abstract] OR blood[Title/Abstract] OR “dried blood spot“[Title/Abstract])Cochrane Library(cytomegalovirus OR CMV) AND (congenital OR perinatal OR newborn OR neonate OR neonatal) AND (diagnos* OR sensitivity OR specificity OR “predictive value*” OR ROC OR “receiver operating characteristic”)ProQuestallintitle: “diagnostic accuracy” OR sensitivity OR specificity OR PCR OR saliva OR urine OR DBS OR blood OR newborn OR neonate “congenital cytomegalovirus”Google Scholar(“congenital cytomegalovirus” OR “congenital CMV”) AND (“diagnostic accuracy” OR sensitivity OR specificity) AND (“dried blood spot” OR DBS OR saliva OR urine) AND PCR Electronic database search strategies for studies on congenital cytomegalovirus diagnostic accuracy Study selection All records retrieved from the database searches were screened independently by title and abstract to assess potential eligibility. Full-text articles were subsequently reviewed for inclusion based on the predefined eligibility criteria. Any disagreements regarding study selection were resolved through discussion. Data extraction From each included study, diagnostic accuracy data were extracted to construct 2 × 2 contingency tables, including true positives (TP), false positives (FP), false negatives (FN), and true negatives (TN). Extracted variables included author and year, index test type, and reference standard. For studies in which 2 × 2 data were not directly reported, these values were reconstructed from reported sensitivity, specificity, and sample size. The number of true positives and false negatives was derived from sensitivity and the number of confirmed cases, while true negatives and false positives were derived from specificity and the number of non-cases. The following standard formulas were used: sensitivity = TP / (TP + FN) and specificity = TN / (TN + FP). Where necessary, calculated values were rounded to the nearest whole number. All reconstructed data were checked for internal consistency prior to inclusion in the meta-analysis. Risk of bias assessment Risk of bias and applicability concerns of the included diagnostic accuracy studies were evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. This instrument assesses methodological quality across four domains: patient selection, index test, reference standard, and flow and timing. Each domain was rated as having low, high, or unclear risk of bias based on signaling questions recommended by the QUADAS-2 framework. Applicability concerns were also assessed for the first three domains. Two reviewers independently assessed each included study, and any discrepancies were resolved through discussion and consensus. Studies were judged as having high risk of bias if they employed non-consecutive or selective sampling, lacked blinding in test interpretation, used an inappropriate reference standard, or applied partial verification. Overall judgments were summarized in graphical format to facilitate interpretation and comparison across studies. Statistical analysis Random-effects meta-analyses were used to pool sensitivity and specificity for DBS and saliva PCR with 95% confidence intervals, accounting for between-study heterogeneity assessed by I² and Cochran’s Q. Subgroup differences by specimen type were evaluated using chi-square tests, and SROC curves with AUCs were constructed to assess overall diagnostic performance. A bivariate random-effects model was applied to jointly pool sensitivity and specificity and derive likelihood ratios and diagnostic odds ratios. All analyses were conducted in R, with p < 0.05 considered statistically significant. Results Selection process The search initially identified 1172 articles from PubMed (286), ProQuest (362), Cochrane Library (73), Google Scholar (398) and other sources (53). After removing duplicates, 1118 articles remained for screening. Based on title and abstract review, 53 articles were selected for full-text assessment. 34 articles were excluded after full-text screening. In the end, 19 articles were included in the review (Fig. 1). Fig. 1PRISMA diagram illustrating the study selection process for the systematic review and meta-analysis PRISMA diagram illustrating the study selection process for the systematic review and meta-analysis Study characteristics A total of 19 studies were included in the analysis, encompassing a combined sample size of 103,669 neonates. Sample sizes varied widely across studies, ranging from 83 participants to 34,989 participants. The number of confirmed congenital CMV cases per study ranged from 5 to 177. Across the included studies, urine PCR was the most frequently used reference standard for confirmation of congenital CMV infection. Several studies employed urine viral culture, while others used saliva culture either alone or in combination with urine PCR or culture. The timing of diagnostic testing was largely within the recommended neonatal window, with most studies performing testing within the first 3 weeks of life. Several studies conducted testing at birth or within the first 7–10 days, while a small number reported testing as “after birth” (Table 2). Table 2Characteristics of included studiesFirst author, yearSample sizeConfirmed casesReference standardTiming of testing[8] (Dollard et al., 2021)12,55456Urine PCR≤ 3 weeks[9] (Barkai et al., 2014)9,84547Urine PCRAfter birth[10] (Cardoso et al., 2015)3335Urine PCR≤ 3 weeks[11] (S. Eventov-Friedman et al., 2019)85658Urine PCRFirst 10 days of life.[12] (Fernandes et al., 2021)149210Urine PCR≤ 2 weeks[13] (Huang et al., 2021)635049Urine PCR≤ 2 weeks[14] (Izquierdo et al., 2023)16428Urine PCR≤ 3 weeks[15] (Pasternak et al., 2020)8342Urine PCRNot Stated[16] (Ross et al., 2017)29626Saliva cultureAt birth[17] (Boppana et al., 2011)34,989177Saliva cultureAt birth[18] (Del Valle Penella et al., 2023)8962Urine PCR/ culture≤ 3 weeks[19] (Izquierdo et al., 2024)218610Urine PCR≤ 3 weeks[20] (Gunkel et al., 2014)26147Urine PCR≤ 3 weeks[21] (Boppana et al., 2010)9,02632Saliva cultureNot reported[22] (Exler et al., 2019)13329Urine PCR0–8 days[23] (Shlonsky et al., 2021)10006Urine PCRAfter birth[24] (Wunderlich et al., 2023)22,07979Urine PCRAfter birth[25] (Vives-Oñós et al., 2019)184103Urine Culture2 weeks[26] (Leruez-Ville et al., 2011)27164Urine PCR≤ 7 days of life Table 2Characteristics of included studiesFirst author, yearSample sizeConfirmed casesReference standardTiming of testing[8] (Dollard et al., 2021)12,55456Urine PCR≤ 3 weeks[9] (Barkai et al., 2014)9,84547Urine PCRAfter birth[10] (Cardoso et al., 2015)3335Urine PCR≤ 3 weeks[11] (S. Eventov-Friedman et al., 2019)85658Urine PCRFirst 10 days of life.[12] (Fernandes et al., 2021)149210Urine PCR≤ 2 weeks[13] (Huang et al., 2021)635049Urine PCR≤ 2 weeks[14] (Izquierdo et al., 2023)16428Urine PCR≤ 3 weeks[15] (Pasternak et al., 2020)8342Urine PCRNot Stated[16] (Ross et al., 2017)29626Saliva cultureAt birth[17] (Boppana et al., 2011)34,989177Saliva cultureAt birth[18] (Del Valle Penella et al., 2023)8962Urine PCR/ culture≤ 3 weeks[19] (Izquierdo et al., 2024)218610Urine PCR≤ 3 weeks[20] (Gunkel et al., 2014)26147Urine PCR≤ 3 weeks[21] (Boppana et al., 2010)9,02632Saliva cultureNot reported[22] (Exler et al., 2019)13329Urine PCR0–8 days[23] (Shlonsky et al., 2021)10006Urine PCRAfter birth[24] (Wunderlich et al., 2023)22,07979Urine PCRAfter birth[25] (Vives-Oñós et al., 2019)184103Urine Culture2 weeks[26] (Leruez-Ville et al., 2011)27164Urine PCR≤ 7 days of life Characteristics of included studies Pooled diagnostic accuracy of DBS PCR and saliva PCR A total of 19 studies included in the quantitative synthesis, comprising DBS PCR and Saliva PCR assays for the diagnosis of congenital CMV. Diagnostic accuracy was assessed separately for specificity and sensitivity, with subgroup analyses conducted according to specimen type (DBS vs. saliva). Sensitivity DBS PCR Six studies contributed to the pooled sensitivity analysis for DBS PCR. Sensitivity estimates varied widely across studies, ranging from 0.34 to 0.97. The pooled sensitivity was 0.72 (95% CI: 0.45–0.89) using a random-effects model. Considerable heterogeneity was present (I² = 90.7%, p < 0.0001) (Table 3A). Saliva PCR Fourteen studies evaluated the sensitivity of saliva PCR. Individual study estimates ranged from 0.78 to 1.00. The pooled sensitivity was 0.95 (95% CI: 0.91–0.97), with moderate heterogeneity (I² = 29.9%, p = 0.14) (Table 3B). Overall sensitivity and subgroup comparison Across all studies combined, the overall pooled sensitivity was 0.91 (95% CI: 0.82–0.96), although substantial heterogeneity remained (I² = 85.6%, p < 0.0001). Subgroup analysis demonstrated a statistically significant difference in sensitivity between DBS PCR and saliva PCR (χ² = 8.22, p = 0.004), with saliva PCR showing significantly higher sensitivity (Table 5). Specificity DBS PCR Six studies evaluated the specificity of DBS PCR. Individual study estimates of specificity ranged from 0.73 to 1.00. The pooled specificity under a random-effects model was 1.00 (95% CI: 0.93–1.00). Substantial heterogeneity was observed (I² = 96.4%, p < 0.0001), indicating considerable between-study variability (Table 4A). Saliva PCR Fourteen studies assessed the specificity of saliva PCR. Most studies reported specificity values close to 1.00, with individual estimates ranging from 0.90 to 1.00. The pooled specificity was 1.00 (95% CI: 0.99–1.00) under a random-effects model. Heterogeneity was also high (I² = 98.2%, p < 0.0001) (Table 4b). Comparison between DBS and saliva When comparing subgroups, no statistically significant difference in specificity was observed between DBS PCR and saliva PCR (χ² = 0.19, p = 0.76), suggesting comparable specificity between the two specimen types (Table 5). Table 3A. Pooled sensitivity of dried blood spot (DBS) PCR for detection of congenital cytomegalovirus. B. Pooled sensitivity of saliva PCR for detection of congenital cytomegalovirusAStudyTPTP + FNSensitivity (95% CI)Weight (%)Dollard 202148560.86 (0.74–0.94)6.5Ross 201711260.42 (0.23–0.63)6.5Del Valle Penella 202352620.84 (0.72–0.92)6.6Boppana 201011320.34 (0.19–0.53)6.5Vives-Onos 2019581030.56 (0.46–0.66)6.8Leruez-Ville 201162640.97 (0.89–1.00)5.6 Random Effects Model - 343 0.72 (0.45–0.89) 38.6 Heterogeneity: I² = 90.7%, p < 0.0001 B Study TP TP + FN Sensitivity (95% CI) Weight (%) Dollard 202152560.93 (0.83–0.98)6.2Barkai 201447471.00 (0.92–1.00)3.6Cardoso 2015450.80 (0.28–0.99)4.4Eventov-Friedman 201957580.98 (0.91–1.00)4.8Fernandes 202110101.00 (0.69–1.00)3.6Huang 202142421.00 (0.92–1.00)3.6Izquierdo 2023790.78 (0.40–0.97)5.4Pasternak 202042421.00 (0.92–1.00)3.6Boppana 201185851.00 (0.96–1.00)3.6Izquierdo 202410101.00 (0.69–1.00)3.6Gunkel 201442470.89 (0.77–0.96)6.3Exler 201927290.93 (0.77–0.99)5.6Shlosnky 2021661.00 (0.54–1.00)3.5Wurlich 202379791.00 (0.95–1.00)3.6 Random Effects Model - 525 0.95 (0.91–0.97) 61.4 Heterogeneity: I² = 29.9%, p = 0.1383 Table 3A. Pooled sensitivity of dried blood spot (DBS) PCR for detection of congenital cytomegalovirus. B. Pooled sensitivity of saliva PCR for detection of congenital cytomegalovirusAStudyTPTP + FNSensitivity (95% CI)Weight (%)Dollard 202148560.86 (0.74–0.94)6.5Ross 201711260.42 (0.23–0.63)6.5Del Valle Penella 202352620.84 (0.72–0.92)6.6Boppana 201011320.34 (0.19–0.53)6.5Vives-Onos 2019581030.56 (0.46–0.66)6.8Leruez-Ville 201162640.97 (0.89–1.00)5.6 Random Effects Model - 343 0.72 (0.45–0.89) 38.6 Heterogeneity: I² = 90.7%, p < 0.0001 B Study TP TP + FN Sensitivity (95% CI) Weight (%) Dollard 202152560.93 (0.83–0.98)6.2Barkai 201447471.00 (0.92–1.00)3.6Cardoso 2015450.80 (0.28–0.99)4.4Eventov-Friedman 201957580.98 (0.91–1.00)4.8Fernandes 202110101.00 (0.69–1.00)3.6Huang 202142421.00 (0.92–1.00)3.6Izquierdo 2023790.78 (0.40–0.97)5.4Pasternak 202042421.00 (0.92–1.00)3.6Boppana 201185851.00 (0.96–1.00)3.6Izquierdo 202410101.00 (0.69–1.00)3.6Gunkel 201442470.89 (0.77–0.96)6.3Exler 201927290.93 (0.77–0.99)5.6Shlosnky 2021661.00 (0.54–1.00)3.5Wurlich 202379791.00 (0.95–1.00)3.6 Random Effects Model - 525 0.95 (0.91–0.97) 61.4 Heterogeneity: I² = 29.9%, p = 0.1383 A. Pooled sensitivity of dried blood spot (DBS) PCR for detection of congenital cytomegalovirus. B. Pooled sensitivity of saliva PCR for detection of congenital cytomegalovirus Heterogeneity: I² = 29.9%, p = 0.1383 Table 4A. Pooled specificity of dried blood spot (DBS) PCR for detection of congenital cytomegalovirus. B. Pooled specificity of saliva PCR for detection of congenital cytomegalovirusAStudyTNTN + FPSpecificity (95% CI)Weight (%)Dollard 202112,49812,4981.00 (1.00–1.00)4.0Ross 20171982700.73 (0.68–0.79)5.6Del Valle Penella 202327271.00 (0.87–1.00)4.0Boppana 2010899389941.00 (1.00–1.00)4.7Vives-Onos 201979810.98 (0.91–1.00)5.1Leruez-Ville 20112052070.99 (0.97–1.00)5.1 Random Effects Model - 22,077 1.00 (0.93–1.00) 28.6 Heterogeneity: I² = 96.4%, p < 0.0001 B Study TN TN + FP Specificity (95% CI) Weight (%) Dollard 202112,48512,4981.00 (1.00–1.00)5.6Barkai 2014978997981.00 (1.00–1.00)5.5Cardoso 20153283281.00 (0.99–1.00)4.0Eventov-Friedman 20197307980.91 (0.89–0.93)5.6Fernandes 2021147814821.00 (0.99–1.00)5.4Huang 2021630163081.00 (1.00–1.00)5.5Izquierdo 2023163316341.00 (1.00–1.00)4.7Pasternak 202041411.00 (0.91–1.00)4.0Boppana 201117,56917,5771.00 (1.00–1.00)5.5Izquierdo 2024217421761.00 (1.00–1.00)5.1Gunkel 20142132141.00 (0.97–1.00)4.7Exler 2019941040.90 (0.83–0.95)5.5Shlosnky 20219939941.00 (0.99–1.00)4.7Wurlich 202321,98522,0001.00 (1.00–1.00)5.6 Random Effects Model - 75,952 1.00 (0.99–1.00) 71.4 Heterogeneity: I² = 98.2%, p < 0.0001 Table 4A. Pooled specificity of dried blood spot (DBS) PCR for detection of congenital cytomegalovirus. B. Pooled specificity of saliva PCR for detection of congenital cytomegalovirusAStudyTNTN + FPSpecificity (95% CI)Weight (%)Dollard 202112,49812,4981.00 (1.00–1.00)4.0Ross 20171982700.73 (0.68–0.79)5.6Del Valle Penella 202327271.00 (0.87–1.00)4.0Boppana 2010899389941.00 (1.00–1.00)4.7Vives-Onos 201979810.98 (0.91–1.00)5.1Leruez-Ville 20112052070.99 (0.97–1.00)5.1 Random Effects Model - 22,077 1.00 (0.93–1.00) 28.6 Heterogeneity: I² = 96.4%, p < 0.0001 B Study TN TN + FP Specificity (95% CI) Weight (%) Dollard 202112,48512,4981.00 (1.00–1.00)5.6Barkai 2014978997981.00 (1.00–1.00)5.5Cardoso 20153283281.00 (0.99–1.00)4.0Eventov-Friedman 20197307980.91 (0.89–0.93)5.6Fernandes 2021147814821.00 (0.99–1.00)5.4Huang 2021630163081.00 (1.00–1.00)5.5Izquierdo 2023163316341.00 (1.00–1.00)4.7Pasternak 202041411.00 (0.91–1.00)4.0Boppana 201117,56917,5771.00 (1.00–1.00)5.5Izquierdo 2024217421761.00 (1.00–1.00)5.1Gunkel 20142132141.00 (0.97–1.00)4.7Exler 2019941040.90 (0.83–0.95)5.5Shlosnky 20219939941.00 (0.99–1.00)4.7Wurlich 202321,98522,0001.00 (1.00–1.00)5.6 Random Effects Model - 75,952 1.00 (0.99–1.00) 71.4 Heterogeneity: I² = 98.2%, p < 0.0001 A. Pooled specificity of dried blood spot (DBS) PCR for detection of congenital cytomegalovirus. B. Pooled specificity of saliva PCR for detection of congenital cytomegalovirus Heterogeneity: I² = 98.2%, p < 0.0001 Table 5Overall pooled diagnostic accuracy of DBS and saliva PCR for detection of congenital cytomegalovirusOutcomeOverall (95% CI)(I², p-value)Test for group difference (χ², p)Sensitivity0.91 (0.82–0.96)85.6%, p < 0.001(χ² = 8.22, p = 0.004)Specificity1.00 (0.99–1.00)98.5%, p < 0.001(χ² = 0.19, p = 0.76) Table 5Overall pooled diagnostic accuracy of DBS and saliva PCR for detection of congenital cytomegalovirusOutcomeOverall (95% CI)(I², p-value)Test for group difference (χ², p)Sensitivity0.91 (0.82–0.96)85.6%, p < 0.001(χ² = 8.22, p = 0.004)Specificity1.00 (0.99–1.00)98.5%, p < 0.001(χ² = 0.19, p = 0.76) Overall pooled diagnostic accuracy of DBS and saliva PCR for detection of congenital cytomegalovirus Fig. 2Summary receiver operating characteristic (SROC) curves for diagnostic performance of (a) saliva PCR and (b) dried blood spot (DBS) PCR in detecting congenital cytomegalovirus Summary receiver operating characteristic (SROC) curves for diagnostic performance of (a) saliva PCR and (b) dried blood spot (DBS) PCR in detecting congenital cytomegalovirus SROC analysis of saliva and DBS PCR The SROC curves demonstrated a higher diagnostic performance for saliva PCR compared to DBS PCR (Fig. 2). The pooled area under the curve (AUC) for saliva PCR was 0.724 (95% CI: 0.649–0.822), indicating moderate diagnostic accuracy, whereas DBS PCR showed lower performance with an AUC of 0.558 (95% CI: 0.511–0.648). Fig. 3Risk of bias and applicability concerns of included studies assessed using the QUADAS-2 tool Risk of bias and applicability concerns of included studies assessed using the QUADAS-2 tool Risk of bias assessment The QUADAS-2 assessment is summarized in Fig. 3. Most studies showed low risk of bias in the index test and reference standard domains, reflecting the use of standardized molecular assays and appropriate diagnostic criteria. However, several studies had high risk of bias in the patient selection and flow and timing domains, mainly due to targeted or retrospective sampling and partial verification of results. Applicability concerns were generally low, although some single-center and selected-population studies showed moderate to high concerns. Overall, the included studies demonstrated acceptable methodological quality, with some limitations related to study design and verification procedures. Table 6Bivariate summary estimates of diagnostic accuracy of saliva PCR and dried blood spot (DBS) PCR for congenital cytomegalovirus (cCMV) detectionTestSe95% CISp95% CILR+LR−DORSaliva PCR0.9440.896–0.9710.9970.992–0.999326.30.065844.8DBS PCR0.7170.453–0.8860.9940.920–1.000127.60.28448.6Se, sensitivity; Sp, specificity; LR+, positive likelihood ratio; LR−, negative likelihood ratio; DOR, diagnostic odds ratio Table 6Bivariate summary estimates of diagnostic accuracy of saliva PCR and dried blood spot (DBS) PCR for congenital cytomegalovirus (cCMV) detectionTestSe95% CISp95% CILR+LR−DORSaliva PCR0.9440.896–0.9710.9970.992–0.999326.30.065844.8DBS PCR0.7170.453–0.8860.9940.920–1.000127.60.28448.6Se, sensitivity; Sp, specificity; LR+, positive likelihood ratio; LR−, negative likelihood ratio; DOR, diagnostic odds ratio Bivariate summary estimates of diagnostic accuracy of saliva PCR and dried blood spot (DBS) PCR for congenital cytomegalovirus (cCMV) detection Se, sensitivity; Sp, specificity; LR+, positive likelihood ratio; LR−, negative likelihood ratio; DOR, diagnostic odds ratio Bivariate diagnostic accuracy Bivariate meta-analysis demonstrated that saliva PCR has superior diagnostic performance for congenital cytomegalovirus (cCMV) detection compared with dried blood spot (DBS) PCR (Table 6). Saliva PCR achieved high pooled sensitivity (0.94, 95% CI: 0.90–0.97) and near-perfect specificity (0.997, 95% CI: 0.992–0.999), yielding an exceptionally high positive likelihood ratio (LR + = 326.3) and a low negative likelihood ratio (LR− = 0.06). The corresponding diagnostic odds ratio (DOR = 5844.8) indicates excellent overall discriminative ability. In contrast, DBS PCR demonstrated substantially lower sensitivity (0.72, 95% CI: 0.45–0.89) while maintaining high specificity (0.994, 95% CI: 0.92–1.00). Although DBS PCR retained good rule-in performance (LR + = 127.6), its higher LR− (0.28) reflects limited capacity to reliably exclude cCMV infection. The overall diagnostic accuracy of DBS PCR was markedly lower than that of saliva PCR, as reflected by a lower DOR (448.6). Discussion This systematic review and meta-analysis evaluated the diagnostic accuracy of saliva PCR and DBS PCR for the detection of cCMV infection in neonates, with the aim of clarifying their relative performance in the context of expanding newborn screening initiatives. By synthesizing data from a large and heterogeneous body of studies, this analysis provides a quantitative comparison of these widely used specimen types and addresses ongoing uncertainty regarding their optimal role in clinical and public health practice. The findings of this meta-analysis, based on pooled data from 19 studies, provide robust evidence of differential diagnostic performance between saliva PCR and DBS PCR. The principal finding is that saliva PCR demonstrates significantly higher pooled sensitivity than DBS PCR while maintaining near-perfect specificity, approaching the diagnostic performance of urine PCR. In contrast, DBS PCR showed substantially lower and more variable sensitivity despite excellent specificity, indicating limited ability to reliably exclude infection when used as a standalone test. While saliva PCR emerges as the diagnostically superior method for early detection of cCMV, DBS PCR retains utility in large-scale or retrospective screening contexts due to its logistical advantages; however, its lower sensitivity necessitates cautious interpretation of negative results and consideration of complementary testing strategies. Subgroup analysis further strengthens these findings, demonstrating a statistically significant difference in sensitivity between saliva PCR and DBS PCR. Saliva PCR exhibited more consistent performance across studies, with lower heterogeneity, whereas DBS PCR showed substantial variability in sensitivity estimates. This heterogeneity likely reflects differences in laboratory methodologies, sample processing, and viral load distribution across study populations. The observed subgroup differences underscore the greater reliability of saliva PCR for early detection and highlight limitations in the standalone use of DBS PCR. In addition, the bivariate analysis provides further insight into the comparative diagnostic performance of the two methods. Saliva PCR demonstrated a markedly higher positive likelihood ratio and lower negative likelihood ratio compared to DBS PCR, indicating a stronger ability to both confirm and exclude congenital CMV infection. Furthermore, the substantially higher diagnostic odds ratio observed for saliva PCR reflects its superior overall discriminative power. In contrast, while DBS PCR maintained good rule-in capability due to its high specificity, its higher negative likelihood ratio indicates a reduced ability to reliably exclude infection. These findings reinforce the overall superiority of saliva PCR as a diagnostic tool and highlight important limitations in the standalone use of DBS PCR. Diagnostic accuracy of saliva PCR versus DBS PCR PCR testing of neonatal saliva has consistently shown superior sensitivity for cCMV compared to DBS. A recent meta-analysis found pooled salivary PCR sensitivity of 98.8% and specificity of 99.9% [27]. Empirical newborn screening studies corroborate this high performance. In a large Minnesota cohort (2016–2022), saliva PCR detected 93.1% of infants with confirmed cCMV infection [28]. In Austria, universal saliva screening achieved 100% sensitivity for the 12 confirmed cases, though specificity was compromised due to contamination [29]. By contrast, DBS PCR generally detects a lower fraction of infections. Early studies found dismal sensitivity of 34% in the 2007–2008 CHIMES trial [8], though modern protocols have improved this. Dollard et al. showed aggregate DBS screening reached 85.7% sensitivity [8], whereas individual lab results were 73–77%. Nonetheless, even the best DBS assays miss a substantial minority of cases: Minnesota’s universal-screen data showed sensitivities of 72.4% and 79.3% [28]. Thus, saliva PCR demonstrates consistently high sensitivity for detecting congenital CMV infection in newborns, though a small proportion of cases may remain undetected [27], whereas DBS PCR will miss roughly 15–30% of cases under current methods. Factors underlying DBS PCR performance variability Multiple technical and biological factors contribute to the heterogeneity in DBS sensitivity. First, the viral load in blood is much lower: neonatal viremia tends to be about 100-fold lower than CMV shedding in saliva or urine [30]. In the CHIMES population, DBS PCR had only 34% sensitivity. In contrast, newer DNA-extraction methods produce higher yields: Dollard et al. noted that the modern QuantaBio DBS elution buffer yields substantially more viral DNA than the older Qiagen kit [8]. This technological advance likely underlies the jump in observed sensitivity from 34% to 75–85% in recent screens. Second, sample collection/handling matters: variations in the number or size of DBS punches, time from birth to collection, and filter paper quality can all affect detection. Improving the protocol so that one 1.5-mm punch sufficed maintained detection in laboratory tests [31]. Third, PCR assay design influences sensitivity. Dollard et al. also showed that incorporating an internal control and running duplicate amplifications were needed to maximize DBS yield [8]. Some studies even apply duplex or multi-target PCR: recent work used two viral gene targets (IE and gB) simultaneously to boost sensitivity, effectively capturing strains with variable gene expression [32]. Finally, infant factors affect performance: symptomatic infants typically have higher viral loads, making them more likely to be detected by DBS PCR. Thus, the clinical sensitivity of DBS may be somewhat higher than the raw analytical sensitivity [8]. All these sources of variability mean that DBS performance can differ by lab and setting. Practical and logistical advantages of DBS PCR Although less sensitive, DBS PCR offers important practical benefits for screening programs. Because heel-prick blood spots are collected from virtually all newborns for metabolic screening, PCR-based CMV testing can be added without a new specimen or direct infant contact [28]. State and regional newborn-screening laboratories already have systems for storing and analyzing DBS cards, enabling both prospective and retrospective screening. Retrospectively, DBS have been used to diagnose otherwise missed infections: Shahar-Nissan et al. showed that PCR on archived DBS identified cCMV in 19 of 436 clinic-referred children (4.4%). Many of those infants had early clinical signs, and universal DBS screening “may have prevented poor hearing and developmental outcomes in 8 of the 19 children” [33]. The advantage is clear: public health departments can add CMV testing to an existing blood-spot workflow, avoiding the need to train staff in saliva collection or burden families. Moreover, DBS are stable at ambient temperature, simplifying transport and batch processing. In large-scale or resource-limited settings, the relative ease of DBS handling and the ability to test pooled or archived cards can outweigh the sensitivity trade-off. Public health implications of targeted and universal screening Screening strategy has a major influence on the detection rate of congenital CMV. Hearing-targeted screening, which is widely implemented, enables early diagnosis and treatment of infants with evident hearing impairment. However, this approach fails to identify most infected infants, as many have normal hearing at birth. Modeling studies indicate that targeted screening detects only 1.5–3% of tested infants, while the majority of late-onset hearing loss cases are first recognized through routine clinical follow-up rather than newborn screening [34]. In fact, simulated and real-world data show that targeted screening “misses nearly all infants who develop late-onset hearing loss” and only captures those with early-onset deficits. Universal screening increases case identification, detecting hundreds more cases per 100 000 live births than sequential targeted approaches [28]. Cost-effectiveness analyses uniformly favor universal approaches: one recent geographically weighted study showed universal screening was more cost-effective than targeted strategies across all demographic strata, even in low-CMV-prevalence neighborhoods [35]. In practical terms, this means that many asymptomatic infants would be diagnosed and monitored under universal screening, whereas they would be entirely missed by targeted protocols. Technological innovations and implementation strategies Ongoing advances aim to close the sensitivity gap for DBS and improve saliva-based screening efficiency. On the DBS front, researchers are refining extraction and amplification methods. Kim et al. applied droplet digital PCR (ddPCR) to DBS. While ddPCR matched the sensitivity of standard PCR at high viral loads, it did not markedly improve detection in low-viremia samples. They demonstrated that an optimized protocol using a single small punch of DBS yielded equivalent CMV detection to the original three-punch method [31]. This reduction in required sample has practical value, since many NBS cards have limited blood. Likewise, multi-locus PCR assays have been shown to enhance sensitivity by catching strain variants or imperfect primer matches. In terms of logistics, sample pooling has emerged as a powerful strategy for saliva screening. Several groups have validated pooled saliva PCR as an efficient approach: by combining 6–8 swabs per test, they report only a 3-cycle Ct shift but nearly complete case detection. In one series, modeling predicted 99.5% sensitivity with pools of 8, and real-world implementation spared 83% of tests [32]. Such pooling could make universal saliva screening feasible in large hospitals or regional labs. Informatics solutions and improved screening algorithms are being piloted. Each of these developments from better extraction kits to novel assay chemistry has the potential to improve the sensitivity or cost-effectiveness of both saliva and DBS methods. Several limitations should be considered. First, substantial heterogeneity was observed, especially in dried blood spot PCR analyses, likely due to differences in laboratory protocols, sample handling, assay platforms, and viral load distributions. Second, most studies were conducted in high-income settings, which may limit generalizability to low- and middle-income countries with constrained resources and variable screening practices. Finally, the meta-analysis used study-level rather than individual participant data, preventing detailed assessment of patient-level factors and introducing potential verification bias from differing reference standards. Conclusion This review demonstrates that saliva PCR has superior sensitivity and comparable specificity to dried blood spot PCR for the detection of congenital cytomegalovirus infection in newborns. While DBS PCR offers important logistical advantages and integration into existing screening programs, its lower and more variable sensitivity limits its effectiveness as a standalone screening tool. These findings support saliva PCR as the preferred method for newborn cCMV screening where feasible, particularly within universal screening strategies aimed at maximizing early case detection.